featured
2014 Top Stories in Oncology: Colorectal Cancer
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Volker H, von Weikersthal LF, Decker T, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). Paper presented at: 2013 ASCO Annual Meeting; May 31-June 4, 2013; Chicago, IL. Abstract LBA 3506.
- Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Paper presented at: 2014 ASCO Annual Meeting; May 30-June 3, 2013; Chicago, IL. Abstract LBA 3.
-
Niedzwiecki D, Lenz H-J, Innocenti F, et al. CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Paper presented at: ESMO 2014 Congress; September 27-20, 2014; Madrid, Spain. Abstract 501O.
Disclosure statements are available on the authors' profiles: